233 related articles for article (PubMed ID: 36421355)
1. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.
Ma X; Ding Y; Qian J; Wan M; Li N; Mao C; Xiao C; Jiang H; Zheng Y; Wu L; Chen X; Xu N
Curr Oncol; 2022 Nov; 29(11):8937-8954. PubMed ID: 36421355
[TBL] [Abstract][Full Text] [Related]
2. Predictive potential of preoperative Naples prognostic score-based nomogram model for the prognosis in surgical resected thoracic esophageal squamous cell carcinoma patients: A retrospective cohort study.
Guo XW; Ji L; Xi XX; Zhao WW; Liu YC; Zhou SB; Ji SJ
Medicine (Baltimore); 2024 May; 103(18):e38038. PubMed ID: 38701277
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of Nomogram-Based Pretreatment Inflammatory Indicators in Patients With Esophageal Squamous Cell Carcinoma Receiving Intensity-Modulated Radiotherapy.
Xu Z; Ke H; Zheng B; Lin C; Zhang Y; Wang L; Lin Y; Ye Y; Cai L; You M; Chen J; Xu Y
Cancer Control; 2023; 30():10732748231185025. PubMed ID: 37339928
[TBL] [Abstract][Full Text] [Related]
4. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
Lu J; Du L; Lei X; Zhang Z
Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
[TBL] [Abstract][Full Text] [Related]
7. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
[TBL] [Abstract][Full Text] [Related]
8. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract][Full Text] [Related]
9. Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma.
Wei T; Ti W; Song Q; Cheng Y
Curr Oncol; 2022 Apr; 29(5):2920-2927. PubMed ID: 35621628
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibitors plus chemotherapy as first-line therapy for stage IV ESCC.
Lu J; Qin Z; Ma J; Yao N; Qu W; Cui L; Yuan S; Yao Y
J Chemother; 2024 May; 36(3):258-263. PubMed ID: 37592822
[TBL] [Abstract][Full Text] [Related]
11. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.
Duan J; Xie Y; Qu L; Wang L; Zhou S; Wang Y; Fan Z; Yang S; Jiao S
J Immunother Cancer; 2018 Oct; 6(1):100. PubMed ID: 30285868
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment.
Da L; Qu Z; Zhang C; Shen Y; Huang W; Zhang Y; Gu K
Front Oncol; 2023; 13():1144875. PubMed ID: 37035159
[TBL] [Abstract][Full Text] [Related]
13. Nomogram for prognosis of patients with esophageal squamous cell cancer after minimally invasive esophagectomy established based on non-textbook outcome.
Xu SJ; Lin LQ; Chen TY; You CX; Chen C; Chen RQ; Chen SC
Surg Endosc; 2022 Nov; 36(11):8326-8339. PubMed ID: 35556169
[TBL] [Abstract][Full Text] [Related]
14. A nomogram based on pretreatment CT radiomics features for predicting complete response to chemoradiotherapy in patients with esophageal squamous cell cancer.
Luo HS; Huang SF; Xu HY; Li XY; Wu SX; Wu DH
Radiat Oncol; 2020 Oct; 15(1):249. PubMed ID: 33121507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and adverse reactions analysis of PD-1/PD-L1 inhibitors in advanced esophageal squamous cell carcinoma.
Wang LL; Xie YX; Liu Y
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):659-667. PubMed ID: 38305608
[TBL] [Abstract][Full Text] [Related]
17. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
Li B; Qin W; Yang L; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
J Transl Med; 2024 Feb; 22(1):195. PubMed ID: 38388379
[TBL] [Abstract][Full Text] [Related]
18. Prognostic nomogram and risk factors for predicting survival in patients with pT2N0M0 esophageal squamous carcinoma.
Kang M; Wang Y; Yang M; Wang X; Zhu L; Zhang M
Sci Rep; 2023 Mar; 13(1):4931. PubMed ID: 36967413
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta-analysis focus on PD-L1 expression level.
Jin Z; Wang J; Sun J; Zhu C; Zhang J; Zhang B
Cancer Rep (Hoboken); 2023 Jul; 6(7):e1794. PubMed ID: 37199321
[TBL] [Abstract][Full Text] [Related]
20. Prognostic nomogram integrated baseline serum lipids for patients with non-esophageal squamous cell carcinoma.
Chen S; Li X; Wen X; Peng S; Xue N; Xing S; Liu Y
Ann Transl Med; 2019 Oct; 7(20):548. PubMed ID: 31807530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
